Literature DB >> 29500915

A fusion-protein approach enabling mammalian cell production of tumor targeting protein domains for therapeutic development.

Jia Hu1,2, Xiang Chen2, Xuhua Zhang2,3, Xiaopeng Yuan2,4, Mingjuan Yang2, Hui Dai5, Wei Yang2, Qinghua Zhou1, Weihong Wen6, Qirui Wang2,7, Weijun Qin8, Aizhi Zhao2.   

Abstract

A single chain Fv fragment (scFv) is a fusion of the variable regions of heavy (VH ) and light (VL ) chains of immunoglobulins. They are important elements of chimeric antigen receptors for cancer therapy. We sought to produce a panel of 16 extracellular protein domains of tumor markers for use in scFv yeast library screenings. A series of vectors comprising various combinations of expression elements was made, but expression was unpredictable and more than half of the protein domains could not be produced using any of the constructs. Here we describe a novel fusion expression system based on mouse TEM7 (tumor endothelial marker 7), which could facilitate protein expression. With this approach we could produce all but one of the tumor marker domains that could not otherwise be expressed. In addition, we demonstrated that the tumor associated antigen hFZD10 produced as a fusion protein with mTEM7 could be used to enrich scFv antibodies from a yeast display library. Collectively our study demonstrates the potential of specific fusion proteins based on mTEM7 in enabling mammalian cell production of tumor targeting protein domains for therapeutic development.
© 2018 The Protein Society.

Entities:  

Keywords:  antibodies; cancer; mammalian cells; recombinant protein expression; scFv; yeast library screening

Mesh:

Substances:

Year:  2018        PMID: 29500915      PMCID: PMC5916118          DOI: 10.1002/pro.3399

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  55 in total

1.  Characterization of Sp17: a ubiquitous three domain protein that binds heparin.

Authors:  Y Wen; R T Richardson; E E Widgren; M G O'Rand
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

Review 2.  Production of recombinant protein therapeutics in cultivated mammalian cells.

Authors:  Florian M Wurm
Journal:  Nat Biotechnol       Date:  2004-11       Impact factor: 54.908

Review 3.  Recombinant protein production by large-scale transient gene expression in mammalian cells: state of the art and future perspectives.

Authors:  Lucia Baldi; David L Hacker; Myriam Adam; Florian M Wurm
Journal:  Biotechnol Lett       Date:  2007-01-19       Impact factor: 2.461

4.  A new tagged-TEV protease: construction, optimisation of production, purification and test activity.

Authors:  Baligh Miladi; Hassib Bouallagui; Cyrine Dridi; Ahmed El Marjou; Guilhem Boeuf; Patrick Di Martino; Florence Dufour; Abdellatif Elm'Selmi
Journal:  Protein Expr Purif       Date:  2010-09-09       Impact factor: 1.650

5.  Purification of glutathione S-transferase fusion proteins as a non-degraded form by using a protease-negative E. coli strain, AD202.

Authors:  H Nakano; T Yamazaki; M Ikeda; H Masai; S Miyatake; T Saito
Journal:  Nucleic Acids Res       Date:  1994-02-11       Impact factor: 16.971

6.  Molecular cloning of Frizzled-10, a novel member of the Frizzled gene family.

Authors:  J Koike; A Takagi; T Miwa; M Hirai; M Terada; M Katoh
Journal:  Biochem Biophys Res Commun       Date:  1999-08-19       Impact factor: 3.575

7.  Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase.

Authors:  D B Smith; K S Johnson
Journal:  Gene       Date:  1988-07-15       Impact factor: 3.688

8.  The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices.

Authors:  Giulio Ghersi; Qiang Zhao; Monica Salamone; Yunyun Yeh; Stanley Zucker; Wen-Tien Chen
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

Review 9.  The cold-shock response in cultured mammalian cells: harnessing the response for the improvement of recombinant protein production.

Authors:  Mohamed B Al-Fageeh; Rosalyn J Marchant; Martin J Carden; C Mark Smales
Journal:  Biotechnol Bioeng       Date:  2006-04-05       Impact factor: 4.530

10.  Microbial factories for recombinant pharmaceuticals.

Authors:  Neus Ferrer-Miralles; Joan Domingo-Espín; José Luis Corchero; Esther Vázquez; Antonio Villaverde
Journal:  Microb Cell Fact       Date:  2009-03-24       Impact factor: 5.328

View more
  1 in total

1.  Secretion of Recombinant Human Annexin V in Fusion with the Super Folder GFP for Labelling Phosphatidylserine-Exposing Membranes.

Authors:  Aya Twair; Issam Kassem; Hossam Murad; Abdul Qader Abbady
Journal:  J Membr Biol       Date:  2021-02-19       Impact factor: 1.843

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.